Category: Uncategorized

VAXCYTE RAISES $1 BILLION JUST AFTER PHASE 3: VAX-31 IS MOVING FROM A CLINICAL ASSET TO A CAPITAL-INTENSIVE COMMERCIAL BET

07/10/2026 Published by HealthBiz

Key Development Just one day after VAX-31 met all primary endpoints in the pivotal OPUS-1 Phase 3 trial, Vaxcyte priced... Read more

Tags: #Global Trends

VIETNAM PROPOSES POSTHUMOUS USE OF A DECEASED HUSBAND’S SPERM: THE BIGGER ISSUE IS NOT IVF — IT IS CONSENT, PARENTAGE AND THE CHILD’S LEGAL RIGHTS

07/10/2026 Published by HealthBiz

Key Development Vietnam's Ministry of Health is proposing a significant expansion of reproductive law: a surviving wife could use her... Read more

Category: Uncategorized

Tags: #Vietnam

QUANG TRI HOSPITAL MOVES APPOINTMENT BOOKING INTO AN APP: DIGITAL TRANSFORMATION ONLY WORKS IF THE PHYSICAL QUEUE DOES NOT BECOME A DIGITAL QUEUE

07/10/2026 Published by HealthBiz

Key Development On October 7, 2026, Quang Tri General Hospital officially launched its patient application, allowing users to book appointments... Read more

Category: Uncategorized

Tags: #Vietnam

VIETNAM REVIEWS NEARLY 32,000 DRUG REGISTRATION DOSSIERS: THE NEXT COMPETITIVE ADVANTAGE IS REGULATORY PREDICTABILITY, NOT PROCESSING VOLUME ALONE

07/10/2026 Published by HealthBiz

Key Development Vietnam has significantly expanded its drug-registration review capacity. But the more important question is whether higher processing volume... Read more

Category: Uncategorized

Tags: #Vietnam

CANCER PATIENTS WAIT 4–6 WEEKS FOR RADIOTHERAPY: VIETNAM’S CHALLENGE IS NOT JUST A MACHINE SHORTAGE — IT IS A SHORTAGE OF EFFECTIVE TREATMENT CAPACITY

07/10/2026 Published by HealthBiz

Key Development When a cancer hospital operates radiotherapy equipment from 5 a.m. until 11 p.m. yet patients still wait weeks... Read more

Category: Uncategorized

Tags: #Vietnam

ARRIVENT’S PHASE 3 FURVENT FAILURE: WHY STRONG TUMOR RESPONSES ARE NO LONGER ENOUGH TO WIN THE LUNG CANCER DRUG RACE

07/10/2026 Published by HealthBiz

ARRIVENT’S PHASE 3 FURVENT FAILURE: WHY STRONG TUMOR RESPONSES ARE NO LONGER ENOUGH TO WIN THE LUNG CANCER DRUG RACE... Read more

Category: Uncategorized

Tags: #Global Trends

MCKESSON–CD&R STRIKE $5.8 BILLION OPTION CARE HEALTH DEAL: THE SPECIALTY PHARMA RACE IS MOVING FROM DRUG DISTRIBUTION TO CONTROL OF THE TREATMENT JOURNEY

07/10/2026 Published by HealthBiz

Key Development McKesson's proposed investment in Option Care Health represents more than diversification into home healthcare. It signals a strategic... Read more

Category: Uncategorized

Tags: #M&A

BD’S $3 BILLION U.S. MANUFACTURING BET: MEDTECH IS MOVING FROM “LOWEST-COST SOURCING” TO “SUPPLY CHAINS BUILT TO SURVIVE DISRUPTION”

06/10/2026 Published by HealthBiz

Key Development Becton Dickinson is becoming part of a broader rethink of medical-device manufacturing: products that look like commodities —... Read more

Category: Uncategorized

Tags: #Global Trends